FLT1 and age-related macular degeneration: Thereby, AFL is capable of neutralizing the ligands of VEGFR1 and VEGFR218 and has received FDA approval for the treatment of age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion, and background DR2.